These lines of evidence suggest that FGF23-induced cardiac hypertrophy is reversible in vitro and in vivo, following the removal of hypertrophic stimulus, and indicate that pharmacological interference with cardiac FGF23/FGFR4 signaling might provide protection from CKD- and age-related LVH [35]. This evidence concerns the gene FGFR4 and cardiac hypertrophy.